Long-term outcomes after treatment for primary aldosteronism

Prognosis of Primary Aldosteronism: A Prospective Cohort Study

This project will follow adults with primary aldosteronism for five years to see how different disease subtypes and treatments affect blood pressure, hormone levels, and heart and kidney health.

Quick facts

• Study type: Observational
• Enrollment: 5000 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Xinjiang Medical University (Academic / other)
• Locations: 2 sites (Chengdu, Sichuan and 1 other locations)
• Trial ID: NCT07378176 on ClinicalTrials.gov

What this trial studies

This is a multicenter prospective cohort enrolling adults with biochemically confirmed primary aldosteronism at two major hospitals in China. Investigators will collect baseline clinical features, etiologic subtypes, diagnostic approaches, and treatment plans, then perform standardized follow-up visits over five years. The study will compare short-term treatment responses and long-term prognosis across pathological subtypes (for example adrenal adenoma versus hyperplasia) and treatment modalities including medication and surgery. Outcomes include rates of blood pressure and hormonal normalization, trajectories of cardiac, renal and vascular damage, metabolic and cognitive changes, and predictors of cardiovascular events.

Who should consider this trial

Good fit: Adults aged 18–80 with a biochemical diagnosis of primary aldosteronism who can provide informed consent and attend follow-up visits are the intended participants.

Not a fit: Patients with severe cardiac, hepatic, or renal failure, those with other forms of secondary hypertension, or those unable to attend follow-up visits are unlikely to benefit from participation or be eligible.

Why it matters

Potential benefit: If successful, the findings could help clinicians choose treatments that better normalize blood pressure and reduce heart and kidney complications in patients with primary aldosteronism in China.

How similar studies have performed: International cohort studies have shown subtype-directed management can improve outcomes, but long-term prospective data specifically in Chinese populations are limited, making this multicenter effort relatively novel for China.

Eligibility criteria

Inclusion Criteria:

1. Aged between 18 and 80 years old.
2. Biochemically confirmed diagnosis of Primary Aldosteronism (PA) according to contemporary guidelines (e.g., confirmed positive case detection test and confirmatory test).
3. Voluntary to sign the informed consent.

Exclusion Criteria:

1. patients with severe cardiac, hepatic or renal dysfunction;
2. Diagnosis of secondary hypertension other than PA.

Where this trial is running

Chengdu, Sichuan and 1 other locations

• The First Affiliated Hospital of Chengdu Medical College — Chengdu, Sichuan, China (Recruiting)
• The First Affiliated Hospital of Xinjiang Medical University — Ürümqi, Xinjiang, China (Recruiting)

Study contacts

• Study coordinator: Xiang Xie, PhD

Conditions Primary Aldosteronism